Walter Reed Army Institute of Research
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Walter Reed Army Institute of Research
CEPI Partners Panacea, THSTI For Pan Beta Coronavirus Vaccines
CEPI will provide up to $12.5m funding for Panacea Biotec and THSTI’s pan-beta coronavirus vaccine candidate, currently in the preclinical stage. Meanwhile, Panacea’s dengue and pneumococcal vaccines are on track for a 2023 launch.
Flexible 'Menu' Of Antibacterial Development Options Suggested By US FDA Panel
FDA should consider allowing sponsors in challenging area of single species antibacterials more flexibility in study designs, advisory committee suggests, despite disagreement over approaches such as animal models and non-inferiority trials.
Tech Transfer Deals, July 2016: Kite Moves Toward Off-The-Shelf T-Cell Therapy
Kite licenses allogeneic cell technology from UCLA that may enable it to create off-the-shelf T-cell therapeutics, augmenting its ongoing development of autologous cancer therapies. See Scrip's monthly update on licensing agreements between companies and universities or other research institutions.
Deals Shaping The Medical Industry, December 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October-November 2014.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.